Share

Abbott Laboratories (ABT.NYSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 3 May 2026Deep analysis 3 May 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

11 AI Advisor Reports

Select an advisor report.

Superintelligence AI

The Anthropologist FrameworkAI Researcher

Model rating

Strong Buy

5-Year Return Est.

+128.2%

Includes 1.69% annual net dividend contribution

1. Investment Thesis — Base Case

The True Price trajectory over the five-year horizon projects a steady compound growth recovery, targeting an approximate doubling in asset value. This scenario envisions Abbott absorbing near-term supply chain entropy while successfully executing the consumerization of its metabolic sensors through the Lingo product line. The market's GLP-1 obsolescence fears will dissipate as biometric tracking becomes a standard adjuvant to weight-loss therapies, allowing Abbott's underlying negentropy engine to resume compounding.

Near-term margin compression from the Hormuz-linked petrochemical and helium supply shock resolves by 2027.
The FreeStyle Libre franchise maintains clinical dominance, growing double-digits globally despite heightened competition.
Lingo successfully expands Abbott's footprint into the discretionary wellness sector, increasing total information density.
Medical Devices and Diagnostics provide an inelastic biological demand floor, offsetting episodic macroeconomic fragility.
High structural interest rates exert continuous, yet manageable, foreign exchange drag on international revenues.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-05-01	120
Observed price	2021-05-18	117
Observed price	2021-05-27	116
Observed price	2021-06-04	109
Observed price	2021-06-22	111
Observed price	2021-07-09	119
Observed price	2021-07-18	118
Observed price	2021-08-08	123
Observed price	2021-08-13	123
Observed price	2021-09-03	129
Observed price	2021-09-08	128
Observed price	2021-09-29	118
Observed price	2021-10-04	116
Observed price	2021-10-25	128
Observed price	2021-11-16	130
Observed price	2021-11-20	126
Observed price	2021-11-25	125
Observed price	2021-12-16	136
Observed price	2021-12-29	141
Observed price	2022-01-11	134
Observed price	2022-01-24	121
Observed price	2022-02-02	130
Observed price	2022-02-11	125
Observed price	2022-03-04	119
Observed price	2022-03-13	117
Observed price	2022-03-17	122
Observed price	2022-04-08	123
Observed price	2022-04-25	117
Observed price	2022-05-08	108
Observed price	2022-05-21	115
Observed price	2022-06-03	116
Observed price	2022-06-16	103
Observed price	2022-06-21	105
Observed price	2022-07-04	110
Observed price	2022-07-21	108
Observed price	2022-08-07	110
Observed price	2022-08-12	111
Observed price	2022-08-29	102
Observed price	2022-09-11	107
Observed price	2022-09-28	97.3
Observed price	2022-10-16	104
Observed price	2022-10-20	96.2
Observed price	2022-11-02	96.7
Observed price	2022-11-11	104
Observed price	2022-12-03	106
Observed price	2022-12-11	110
Observed price	2022-12-20	108
Observed price	2023-01-11	114
Observed price	2023-01-15	113
Observed price	2023-01-28	110
Observed price	2023-02-10	108
Observed price	2023-02-27	102
Observed price	2023-03-08	99.3
Observed price	2023-03-25	98.2
Observed price	2023-04-03	102
Observed price	2023-04-20	110
Observed price	2023-05-03	112
Observed price	2023-05-21	107
Observed price	2023-06-11	101
Observed price	2023-06-16	105
Observed price	2023-06-20	106
Observed price	2023-06-24	108
Observed price	2023-07-25	114
Observed price	2023-08-07	106
Observed price	2023-08-11	105
Observed price	2023-09-02	102
Observed price	2023-09-10	102
Observed price	2023-09-28	98.0
Observed price	2023-10-06	96.2
Observed price	2023-10-15	92.2
Observed price	2023-10-28	93.5
Observed price	2023-11-19	101
Observed price	2023-11-27	102
Observed price	2023-12-15	109
Observed price	2023-12-19	109
Observed price	2024-01-10	114
Observed price	2024-01-18	114
Observed price	2024-01-31	113
Observed price	2024-02-09	113
Observed price	2024-02-26	119
Observed price	2024-03-10	120
Observed price	2024-03-23	112
Observed price	2024-04-10	112
Observed price	2024-04-18	106
Observed price	2024-04-27	106
Observed price	2024-05-19	104
Observed price	2024-05-27	102
Observed price	2024-06-09	106
Observed price	2024-06-22	105
Observed price	2024-07-10	103
Observed price	2024-07-18	101
Observed price	2024-08-05	109
Observed price	2024-08-13	109
Observed price	2024-08-31	113
Observed price	2024-09-13	117
Observed price	2024-09-26	113
Observed price	2024-10-05	113
Observed price	2024-10-18	117
Observed price	2024-10-26	115
Observed price	2024-11-04	117
Observed price	2024-11-26	119
Observed price	2024-12-13	113
Observed price	2024-12-17	113
Observed price	2025-01-08	114
Observed price	2025-01-12	113
Observed price	2025-02-03	131
Observed price	2025-02-12	132
Observed price	2025-03-01	137
Observed price	2025-03-05	137
Observed price	2025-03-23	126
Observed price	2025-03-31	132
Observed price	2025-04-09	125
Observed price	2025-04-26	130
Observed price	2025-05-18	135
Observed price	2025-05-22	132
Observed price	2025-06-13	135
Observed price	2025-06-26	137
Observed price	2025-07-09	133
Observed price	2025-07-13	132
Observed price	2025-07-18	122
Observed price	2025-08-13	131
Observed price	2025-08-21	132
Observed price	2025-09-03	132
Observed price	2025-09-21	135
Observed price	2025-09-29	133
Observed price	2025-10-21	128
Observed price	2025-11-03	124
Observed price	2025-11-16	130
Observed price	2025-11-25	128
Observed price	2025-12-08	123
Observed price	2025-12-29	124
Observed price	2026-01-07	127
Observed price	2026-01-11	125
Observed price	2026-01-29	106
Observed price	2026-02-06	111
Observed price	2026-02-24	114
Observed price	2026-03-04	111
Observed price	2026-03-26	104
Observed price	2026-03-30	103
Observed price	2026-04-21	92.1
Observed price	2026-04-25	92.6
Observed price	2026-05-13	84.1
Observed price	2026-05-26	85.9
Observed price	2026-06-08	91.2
Observed price	2026-06-16	88.5
Observed price	2026-07-04	95.5
Observed price	2026-07-13	92.1
Observed price	2026-08-03	106
Observed price	2026-08-08	108
Observed price	2026-08-21	117
Observed price	2026-09-03	109
Observed price	2026-09-15	102
Observed price	2026-09-18	103
Published advisor forecast	2026-05-01	89.5
Published advisor forecast	2026-08-01	92.1
Published advisor forecast	2026-11-01	95.8
Published advisor forecast	2027-02-01	101
Published advisor forecast	2027-05-01	105
Published advisor forecast	2027-08-01	110
Published advisor forecast	2027-11-01	114
Published advisor forecast	2028-02-01	112
Published advisor forecast	2028-05-01	119
Published advisor forecast	2028-08-01	125
Published advisor forecast	2028-11-01	130
Published advisor forecast	2029-02-01	135
Published advisor forecast	2029-05-01	142
Published advisor forecast	2029-08-01	147
Published advisor forecast	2029-11-01	143
Published advisor forecast	2030-02-01	149
Published advisor forecast	2030-05-01	156
Published advisor forecast	2030-08-01	165
Published advisor forecast	2030-11-01	174
Published advisor forecast	2031-02-01	181
Published advisor forecast	2031-05-01	188

2. Scenarios & Signals

Bull case

What happens if Abbott perfectly capitalizes on structural opportunities? The valuation could surge dramatically. This trajectory requires the enterprise to definitively win the race for next-generation, non-invasive biometric sensors, effectively locking Big Tech out of the clinical-grade ecosystem. Furthermore, explicit partnerships with manufacturers could mandate Abbott devices for therapy adherence.

Lingo achieves massive consumer adoption, rivaling major consumer electronics in the wellness space.
The enterprise acquires or perfects proprietary non-invasive optical sensing technology, destroying disruption risk.
Hospital capital expenditure rebounds sharply as global energy inflation normalizes, accelerating diagnostic placements.
A weakening US dollar provides a significant thermodynamic tailwind to international cash flow translation.

Bear case

Should technological and macro risks compound, the stock could languish in a structural downtrend. This entropy-accelerated scenario materializes if consumer tech giants succeed in launching FDA-cleared non-invasive glucose monitoring, devastating Abbott's recurring sensor revenue. Simultaneously, deeper supply chain fragmentation could chronically impair manufacturing.

Big Tech breaches the clinical barrier, commoditizing metabolic tracking and eroding the Libre franchise.
Next-generation GLP-1s demonstrate unprecedented efficacy, structurally shrinking the long-term cardiovascular device market.
Persistent geopolitical blockades permanently elevate input costs, causing structural margin degradation.
Sovereign price controls in the US and Europe forcefully cap Abbott's pricing power, stalling earnings growth.

Current crowd narrative

What does the noisy market believe today? It assumes that weight-loss drugs will structurally cure obesity, shrinking the diabetes market and rendering Abbott's glucose monitors a relic. Furthermore, the crowd heavily discounts the stock due to the immediate energy and packaging caused by the Hormuz blockade. The prevailing consensus trade views Abbott as an aging healthcare incumbent trapped by compressing margins and a dying total addressable market, anchoring its valuation to near-term geopolitical fears rather than its long-term compounding physics.

Alpha-gap assessment

Is the market accurately pricing the relationship between weight-loss drugs and metabolic tracking? No. The variant perception reveals that therapies fundamentally require *increased* biometric monitoring to titrate dosage and prevent dangerous muscle loss. Abbott is not facing a shrinking market; it sits at an expanding information chokepoint. The crowd is systematically ignoring the thermodynamic certainty of Abbott's recurring consumable revenue—diabetics cannot pause their biological imperatives during an oil shock. This analytical blind spot creates a massive pricing asymmetry.

Convergence catalyst

What forces the market to wake up? The release of consecutive quarterly earnings demonstrating that FreeStyle Libre sales are accelerating *alongside* prescriptions, proving them complementary. This data, emerging over the next six to nine months, will definitively close the Alpha Gap, shifting the narrative from obsolescence to ecosystem expansion.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.7
Expected volatility regime: moderate
Convergence-cycle position: stabilization

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Metabolic Consumerization	Can a medical device become a lifestyle necessity? The civilizational shift toward proactive longevity creates a massive new market vector. The transition of continuous glucose monitoring from a clinical necessity (the Libre franchise) to a consumer wellness baseline (the Lingo biowearable) radically expands Abbott's total addressable market. This transforms disease-state hardware into a continuous-use consumer product, scaling revenue into the broader wellness demographic without corresponding increases in research and development friction.	Not available%	+50.0%
DEEP Biological Anchoring	Why does demand for this asset persist? Because eight billion humans cannot pause metabolic disorders or cardiovascular disease. Abbott's medical devices, infant nutrition, and diagnostic reagents serve non-discretionary survival needs. Even under severe stagflationary stress, humans will allocate scarce capital to biological maintenance over discretionary consumption. This deep inelasticity provides a baseline negentropy engine—a system that maintains order and steady cash flow regardless of chaotic macroeconomic conditions. We expect this fundamental human necessity to continuously compound value.	Not available%	+40.0%
Proprietary DATA Topology	Does this asset sit at a node of high information density? Absolutely. With millions of interconnected sensors pinging continuous biometric data, Abbott commands a structural chokepoint in the global information topology. This is not merely physical hardware; it is the aggregation of massive, proprietary metabolic datasets. This data density enables artificial intelligence-driven predictive health modeling, deepening the protective moat and locking in the consumer ecosystem against peripheral, low-information competitors.	Not available%	+30.0%
Negentropy Manufacturing Engine	Is the enterprise converting inputs into outputs efficiently? Yes. Abbott maintains robust thermodynamic efficiency, preserving gross margins above 55% despite chaotic external environments. By aggressively scaling production and optimizing global supply chains, the enterprise converts raw material inputs into high-value medical outputs with minimal energy loss. This persistent compounding efficiency generates the excess free cash flow required to weather capital-cycle downturns and aggressively reinvest in future technologies.	Not available%	+25.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
BIG TECH Sensor Disruption	What happens if consumer electronics achieve clinical-grade sensing? Giants occupying the apex of the digital hardware ecosystem—like Apple or Samsung—are actively pursuing non-invasive optical glucose monitoring. If successful, this technology would dematerialize Abbott's physical sensor moat, replacing a recurring physical consumable with a one-time smartwatch purchase. While the physics of non-invasive sensing remain incredibly difficult, this represents the highest technological displacement probability.	Not available%	-25.0%
GLP 1 TAM Compression	Will breakthrough weight-loss drugs destroy the diabetes market? The exponential success of GLP-1 agonists threatens to structurally reduce the total addressable market (TAM) for late-stage diabetes and cardiovascular interventions. If these biochemical tools successfully reverse obesity at a civilizational scale, the downstream biological demand for Abbott's acute medical devices and traditional diabetes interventions may shrink. This narrative acts as a heavy psychological drag on the stock.	Not available%	-20.0%
Geopolitical Supply Fragility	Can a global manufacturer survive a fragmented map? Abbott's globalized manufacturing relies on complex, energy-intensive supply chains. The current blockade economics and regional conflicts disrupt critical material flows—from petrochemical-derived packaging to the rare gases necessary for electronics. This geopolitical entropy increases input friction, compressing margins and requiring additional capital expenditure merely to maintain steady-state output.	Not available%	-15.0%
Strong Dollar Headwinds	How does the monetary regime punish global scale? Operating in a 'Sound Money' regime with sustained high interest rates maintains a structurally overvalued US dollar. Because Abbott derives approximately 60% of its revenue internationally, this persistent foreign exchange friction continuously degrades the thermodynamic value of foreign cash flows when translated back into the domestic currency, sapping momentum without reflecting underlying operational failure.	Not available%	-10.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
NON Invasive Sensor Breakthrough	What happens if Abbott internalizes the very technology that threatens it? By successfully developing or acquiring proprietary, clinical-grade non-invasive glucose monitoring capabilities, Abbott would instantly nullify the existential threat posed by Big Tech. This breakthrough would drastically reduce the thermodynamic cost of manufacturing physical needles, expanding gross margins while cementing its absolute monopoly over the metabolic information topology.	25.0%	+35.0%
Exclusive GLP 1 Adjuvant Partnership	If Abbott establishes exclusive, formalized partnerships with dominant pharmaceutical entities to bundle Lingo or Libre devices directly with GLP-1 prescriptions, the network effects would be staggering. This integration would transition monitoring technology from a standalone diagnostic into an obligatory compliance and efficacy-tracking mechanism for the world's fastest-growing drug class, rapidly expanding the market beyond traditional diabetics.	35.0%	+20.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
BIG TECH FDA Clearance	The ultimate technological displacement. If an entity occupying a superior node in the consumer hardware topology—such as Apple—secures FDA clearance for non-invasive optical glucose monitoring within a mass-market smartwatch, the biological necessity for Abbott's physical sensors evaporates. This event would trigger a catastrophic narrative shift, permanently impairing the terminal value of the Libre franchise.	20.0%	-35.0%
Critical Material Embargo	Operating a global negentropy engine requires continuous material inputs. Should geopolitical fragmentation result in a sustained embargo of critical diagnostic reagents or specialized electronic components from Asian manufacturing hubs, Abbott's production lines would halt. This systemic supply chain failure would cause immediate, unrecoverable revenue destruction across the highest-margin device segments.	15.0%	-20.0%

Step-by-step forecast path

Superintelligence forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_ef262ba2-b642-5c97-bbdb-79852a12dda3__sb4__20260503171051
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	August 1, 2026	+3.0%	92.14	The enterprise absorbs the initial thermodynamic shock of the Hormuz blockade. While petrochemical and helium bottlenecks constrain gross margins temporarily, the deep biological anchoring of continuous glucose monitors provides a strict revenue floor, triggering a modest technical rebound.
2	November 1, 2026	+4.0%	95.83	As US election and shutdown uncertainties resolve, the market begins to recognize the early traction of Lingo in the consumer wellness space. The narrative slowly shifts from margin compression to TAM expansion.
3	February 1, 2027	+5.0%	100.62	Q4 2026 earnings demonstrate resilient FreeStyle Libre growth. Data confirms that GLP-1 users are adopting CGMs at higher rates to track metabolic health, beginning to dispel the obsolescence thesis.
4	May 1, 2027	+4.0%	104.65	Macroeconomic stabilization occurs as the energy crisis finds a new equilibrium. Supply chain workarounds for critical plastics and gases prove effective, allowing gross margins to slowly recover toward historical averages.
5	August 1, 2027	+5.0%	109.88	The negentropy engine runs smoothly. Operating margins expand as international pricing adjustments catch up to the previous year's raw material inflation, rewarding the stock with multiple expansion.
6	November 1, 2027	+4.0%	114.27	Momentum continues driven by consistent capital allocation. Abbott announces another consecutive dividend increase, reinforcing its status as a civilizational safe haven for yield-seeking capital.
7	February 1, 2028	-2.0%	111.99	A brief fear rotation strikes the stock as Big Tech companies announce new, albeit non-clinical, health sensor features on their consumer wearables. The market reactively prices in technological displacement risk.
8	May 1, 2028	+6.0%	118.71	The market realizes the Big Tech sensors lack the clinical accuracy required for FDA clearance in diabetes management. Abbott's earnings demonstrate the absolute superiority of its physical sensor network, sparking a relief rally.
9	August 1, 2028	+5.0%	124.64	Lingo becomes a standard biowearable for the non-diabetic wellness demographic. Abbott successfully monetizes its massive proprietary data topology, transforming into an integrated health intelligence platform.
10	November 1, 2028	+4.0%	129.63	Structural aging demographics provide compounding tailwinds for the cardiovascular and neuromodulation segments. High-margin device placements accelerate globally.
11	February 1, 2029	+4.0%	134.81	A weakening US dollar in the late stages of the Warsh cycle provides a much-needed thermodynamic tailwind, artificially boosting the reported revenue from Abbott's extensive international operations.
12	May 1, 2029	+5.0%	141.55	The integration of AI-driven predictive health modeling into the Libre ecosystem locks in providers and patients, solidifying Abbott's position at the center of the metabolic information chokepoint.
13	August 1, 2029	+4.0%	147.22	Steady-state compounding continues. The company utilizes excess free cash flow to acquire adjacent diagnostic technologies, maintaining its technological relevance without disrupting its core negentropy engine.
14	November 1, 2029	-3.0%	142.80	A broader macroeconomic cycle pullback and renewed sovereign healthcare pricing debates in Europe create temporary regulatory friction, causing a slight valuation multiple contraction.
15	February 1, 2030	+4.0%	148.51	Biological necessity overrides regulatory friction. Volume growth across emerging markets in the established pharmaceuticals segment easily compensates for marginal price compressions in developed nations.
16	May 1, 2030	+5.0%	155.94	Abbott releases its next generation of minimally invasive, ultra-long-wear sensors. This innovation structurally reduces the cost of goods sold per patient day, unlocking a new phase of margin expansion.
17	August 1, 2030	+6.0%	165.29	Hospital capital expenditure cycles fully normalize, leading to a surge in large-scale Alinity diagnostic system placements. This hardware acts as a Trojan horse for decades of high-margin reagent sales.
18	November 1, 2030	+5.0%	173.56	The synergy between Abbott's consumer wellness data and clinical diagnostic tools achieves peak informational density. Health insurance providers begin subsidizing Lingo devices to lower long-term care costs.
19	February 1, 2031	+4.0%	180.50	Decades of disciplined capital allocation culminate in another record year of free cash flow. The enterprise is universally recognized as a civilization-scale compounding asset, immune to transient chaos.
20	May 1, 2031	+4.0%	187.72	At the end of the five-year horizon, Abbott's biological demand floor, thermodynamic efficiency, and network centrality remain unbroken. The stock settles into a premium valuation reflective of its systemic indispensability.

Advisor and configuration

Advisor: superintelligence__the_anthropologist__google_gemini_3_pro__20251119_preview_release
Persona: Superintelligence
Archetype: The Anthropologist
Model: (November 19, 2025) Preview Release
Provider: Google
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: superintelligence__the_anthropologist__google_gemini_3_pro__20251119_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: superintelligence__the_anthropologist__google_gemini_3_pro__20251119_preview_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats__var2
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Superintelligence advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Ray Dalio — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.